PL1670768T3 - Związki i sposoby leczenia dyslipidemii - Google Patents
Związki i sposoby leczenia dyslipidemiiInfo
- Publication number
- PL1670768T3 PL1670768T3 PL04793889T PL04793889T PL1670768T3 PL 1670768 T3 PL1670768 T3 PL 1670768T3 PL 04793889 T PL04793889 T PL 04793889T PL 04793889 T PL04793889 T PL 04793889T PL 1670768 T3 PL1670768 T3 PL 1670768T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- methods
- treating dyslipidemia
- treating
- dyslipidemia
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 title 1
- 208000017170 Lipid metabolism disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50973603P | 2003-10-08 | 2003-10-08 | |
| EP04793889A EP1670768B1 (en) | 2003-10-08 | 2004-10-07 | Compounds and methods for treating dyslipidemia |
| PCT/US2004/030907 WO2005037796A1 (en) | 2003-10-08 | 2004-10-07 | Compounds and methods for treating dyslipidemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1670768T3 true PL1670768T3 (pl) | 2010-01-29 |
Family
ID=34465112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04793889T PL1670768T3 (pl) | 2003-10-08 | 2004-10-07 | Związki i sposoby leczenia dyslipidemii |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7749992B2 (pl) |
| EP (2) | EP1670768B1 (pl) |
| JP (1) | JP4773969B2 (pl) |
| KR (1) | KR20060085675A (pl) |
| CN (1) | CN1863778A (pl) |
| AT (1) | ATE442358T1 (pl) |
| AU (1) | AU2004282101A1 (pl) |
| BR (1) | BRPI0414186A (pl) |
| CA (1) | CA2537942A1 (pl) |
| CY (1) | CY1110537T1 (pl) |
| DE (1) | DE602004023100D1 (pl) |
| DK (1) | DK1670768T3 (pl) |
| EA (1) | EA200600737A1 (pl) |
| EC (1) | ECSP066484A (pl) |
| ES (1) | ES2332051T3 (pl) |
| HR (1) | HRP20090581T1 (pl) |
| IL (1) | IL173819A0 (pl) |
| MA (1) | MA28268A1 (pl) |
| MX (1) | MXPA06003927A (pl) |
| NO (1) | NO20062074L (pl) |
| PL (1) | PL1670768T3 (pl) |
| PT (1) | PT1670768E (pl) |
| SI (1) | SI1670768T1 (pl) |
| WO (1) | WO2005037796A1 (pl) |
| ZA (1) | ZA200602888B (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE402180T1 (de) * | 2004-03-26 | 2008-08-15 | Lilly Co Eli | Verbindungen zur behandlung von dyslipidemie |
| BRPI0512523A (pt) | 2004-06-24 | 2008-03-11 | Lilly Co Eli | composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7790770B2 (en) * | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7652023B2 (en) * | 2005-11-23 | 2010-01-26 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| TWI450896B (zh) * | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸 |
| CN103833636B (zh) * | 2014-03-31 | 2015-09-02 | 武汉武药制药有限公司 | 一种莫扎伐普坦中间体的合成方法 |
| AU2016302755B2 (en) * | 2015-07-31 | 2020-09-10 | Arena Pharmaceuticals, Inc. | 5-HT2C receptor agonists and compositions and methods of use |
| EP3588064B1 (en) * | 2017-02-23 | 2022-09-07 | IHI Corporation | Oh radical detection probe, oh radical measurement device, and oh radical measurement method |
| CR20210207A (es) | 2018-10-24 | 2021-09-02 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| US20230149408A1 (en) | 2020-04-15 | 2023-05-18 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| CN113636977B (zh) * | 2021-09-01 | 2022-12-20 | 温州大学 | 2-芳基苯并氮杂卓及其衍生物的合成方法 |
| CN117088814A (zh) * | 2023-02-16 | 2023-11-21 | 烟台大学 | 一种三氟甲硫化氮杂-8/9元环化合物的制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2905909B2 (ja) * | 1991-04-19 | 1999-06-14 | 大塚製薬株式会社 | バソプレシン拮抗剤 |
| TW270927B (pl) | 1992-10-16 | 1996-02-21 | Otsuka Pharma Co Ltd | |
| US5484783A (en) | 1994-03-24 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives |
| WO1995025532A1 (en) | 1994-03-24 | 1995-09-28 | Merrell Pharmaceuticals Inc. | Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives |
| DE69535486T2 (de) | 1994-06-15 | 2008-04-10 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclische Verbindungen verwendbar als Vasopressin- oder Oxytocin-Modulatoren |
| GB9523526D0 (en) | 1995-11-17 | 1996-01-17 | Zeneca Ltd | Therapeutic compounds |
| JPH09214746A (ja) | 1996-02-02 | 1997-08-15 | Ricoh Co Ltd | 画像出力システム及び画像形成装置 |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
| DE19627430A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
| US6333349B1 (en) | 1997-02-26 | 2001-12-25 | Aventis Pharma Deutschland Gmbh | Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them |
| DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
| JPH10287662A (ja) | 1997-04-08 | 1998-10-27 | Kitasato Inst:The | Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法 |
| JP2959765B2 (ja) | 1997-12-12 | 1999-10-06 | 日本たばこ産業株式会社 | ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| HN2000000203A (es) | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
| CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
| US6664522B2 (en) * | 2000-03-30 | 2003-12-16 | Homer L. Spencer | Method and apparatus for sealing multiple casings for oil and gas wells |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| CA2445693A1 (en) | 2001-04-30 | 2002-11-07 | Pfizer Products Inc. | Compounds useful as intermediates for 4-aminoquinoline derivatives |
| PL368850A1 (pl) | 2001-06-21 | 2005-04-04 | Pfizer Products Inc. | Samoemulgujące preparaty inhibitorów białka przenoszącego estry cholesterylu |
| DE10148436A1 (de) | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
| JP2005522424A (ja) * | 2002-02-01 | 2005-07-28 | ファイザー・プロダクツ・インク | コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態 |
| DE60335545D1 (de) | 2002-07-01 | 2011-02-10 | Cytec Surface Specialties Sa | Wasserverdünnbare polymervorläufer sowie herstellung und verwendung davon |
| US7332514B2 (en) | 2002-08-30 | 2008-02-19 | Japan Tobacco Inc. | Dibenzylamine compound and medicinal use thereof |
| KR20050055747A (ko) | 2002-10-04 | 2005-06-13 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 염증 질환 치료용의 ｐｇｄ2 수용체 길항제 |
| WO2004078730A2 (en) | 2003-03-04 | 2004-09-16 | Takasago International Corporation | Method for producing optically active amines |
| US20040204450A1 (en) | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| EP1670765A2 (en) | 2003-09-30 | 2006-06-21 | Pfizer Products Inc. | Cetp inhibitors and metabolites thereof |
| ATE402180T1 (de) | 2004-03-26 | 2008-08-15 | Lilly Co Eli | Verbindungen zur behandlung von dyslipidemie |
| BRPI0512523A (pt) | 2004-06-24 | 2008-03-11 | Lilly Co Eli | composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto |
-
2004
- 2004-10-07 AU AU2004282101A patent/AU2004282101A1/en not_active Abandoned
- 2004-10-07 PL PL04793889T patent/PL1670768T3/pl unknown
- 2004-10-07 CN CNA2004800295407A patent/CN1863778A/zh active Pending
- 2004-10-07 PT PT04793889T patent/PT1670768E/pt unknown
- 2004-10-07 DE DE602004023100T patent/DE602004023100D1/de not_active Expired - Lifetime
- 2004-10-07 KR KR1020067006837A patent/KR20060085675A/ko not_active Ceased
- 2004-10-07 EP EP04793889A patent/EP1670768B1/en not_active Expired - Lifetime
- 2004-10-07 JP JP2006533949A patent/JP4773969B2/ja not_active Expired - Fee Related
- 2004-10-07 DK DK04793889T patent/DK1670768T3/da active
- 2004-10-07 SI SI200431294T patent/SI1670768T1/sl unknown
- 2004-10-07 US US10/574,649 patent/US7749992B2/en not_active Expired - Fee Related
- 2004-10-07 CA CA002537942A patent/CA2537942A1/en not_active Abandoned
- 2004-10-07 HR HR20090581T patent/HRP20090581T1/hr unknown
- 2004-10-07 WO PCT/US2004/030907 patent/WO2005037796A1/en not_active Ceased
- 2004-10-07 BR BRPI0414186-5A patent/BRPI0414186A/pt not_active Application Discontinuation
- 2004-10-07 EA EA200600737A patent/EA200600737A1/ru unknown
- 2004-10-07 ES ES04793889T patent/ES2332051T3/es not_active Expired - Lifetime
- 2004-10-07 AT AT04793889T patent/ATE442358T1/de active
- 2004-10-07 EP EP09157118A patent/EP2098512A1/en not_active Withdrawn
- 2004-10-07 MX MXPA06003927A patent/MXPA06003927A/es not_active Application Discontinuation
-
2006
- 2006-02-20 IL IL173819A patent/IL173819A0/en unknown
- 2006-04-05 EC EC2006006484A patent/ECSP066484A/es unknown
- 2006-04-07 ZA ZA200602888A patent/ZA200602888B/en unknown
- 2006-05-03 MA MA28999A patent/MA28268A1/fr unknown
- 2006-05-08 NO NO20062074A patent/NO20062074L/no not_active Application Discontinuation
-
2009
- 2009-11-05 CY CY20091101151T patent/CY1110537T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1670768T1 (sl) | 2010-01-29 |
| EP1670768A1 (en) | 2006-06-21 |
| DE602004023100D1 (de) | 2009-10-22 |
| US7749992B2 (en) | 2010-07-06 |
| NO20062074L (no) | 2006-05-08 |
| AU2004282101A1 (en) | 2005-04-28 |
| ZA200602888B (en) | 2007-11-28 |
| CA2537942A1 (en) | 2005-04-28 |
| DK1670768T3 (da) | 2009-11-09 |
| EP1670768B1 (en) | 2009-09-09 |
| WO2005037796A1 (en) | 2005-04-28 |
| PT1670768E (pt) | 2009-11-20 |
| JP2007508301A (ja) | 2007-04-05 |
| US20070254869A1 (en) | 2007-11-01 |
| MXPA06003927A (es) | 2008-02-07 |
| BRPI0414186A (pt) | 2006-10-31 |
| JP4773969B2 (ja) | 2011-09-14 |
| ES2332051T3 (es) | 2010-01-25 |
| CN1863778A (zh) | 2006-11-15 |
| KR20060085675A (ko) | 2006-07-27 |
| IL173819A0 (en) | 2006-07-05 |
| EA200600737A1 (ru) | 2006-10-27 |
| MA28268A1 (fr) | 2006-11-01 |
| CY1110537T1 (el) | 2015-04-29 |
| EP2098512A1 (en) | 2009-09-09 |
| HRP20090581T1 (hr) | 2009-12-31 |
| ECSP066484A (es) | 2006-10-10 |
| ATE442358T1 (de) | 2009-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL177962A0 (en) | Compounds and methods for treating dyslipidemia | |
| CY1110537T1 (el) | Ενωσεις και μεθοδοι για την αγωγη της δυσλιπιδαιμιας | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| IL180277A0 (en) | Compounds and methods for treating dyslipidemia | |
| NO20070606L (no) | Inhibitorer av IAP | |
| SE0302811D0 (sv) | Novel compounds | |
| PT1625126E (pt) | Imidazo- e tiazolopiridinas como inibidores de cinase jak3 | |
| SE0301446D0 (sv) | New Compounds | |
| TW200505920A (en) | Organic compounds | |
| TW200510317A (en) | Caspase inhibitors and uses thereof | |
| PL376324A1 (pl) | Piperazynylo-i diazepanylobenzamidy oraz benzotioamidy | |
| MY141583A (en) | Novel fused heterocycles and uses thereof | |
| SE0303541D0 (sv) | New compounds | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| NO20064344L (no) | Caspaseinhibitorer og anvendelser derav | |
| SE0303280D0 (sv) | Novel compounds | |
| SE0302755D0 (sv) | Novel compounds |